A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)

Journal article

Peer reviewed

R. M. Stone, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, L. E. Damon, J. H. Jang, M. S. Tallman, …

Journal of clinical oncology, Vol.29(15_suppl), pp.6520-6520

2011-05-20

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Acute Myeloid Leukemia
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)
Creators: R. M. Stone
S. L. Allen
A. Pigneux
R. K. Stuart
M. Wetzler
D. Rizzieri
H. P. Erba
L. E. Damon
J. H. Jang
M. S. Tallman
K. Warzocha
T. Masszi
M. A. Sekeres
E. Miklos
H. Horst
D. L. D. Selleslag
S. R. Solomon
P. Venugopal
A. S. Lundberg
B. L. Powell
Publication Details: Journal of clinical oncology, Vol.29(15_suppl), pp.6520-6520
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757742802976